Please login to the form below

Not currently logged in
Email:
Password:

Roche's Tarceva gets approval from NICE

The National Institute for Health and Clinical Excellence has approved Roche’s lung cancer drug Tarceva for use on the NHS after the Swiss company agreed to reduce the price

The National Institute for Health and Clinical Excellence (NICE) has approved Roche's lung cancer drug Tarceva for use on the NHS after the Swiss company agreed to reduce the price.

NICE guidance states that Tarceva is recommended as an alternative to sanofi-aventis' Taxotere for patients with non-small cell lung cancer (NSCLC) who have failed to respond to one round of chemotherapy treatment.

Tarceva, which is administered in tablet form (rather than by injection), is offered to the NHS at a price about 15 per cent less than previously meaning the total costs would equal those of Taxotere. NICE states in its guidance documents that sanofi-aventis has offered a discount of at least 12.5 per cent on the list price of Taxotere for NHS trusts.

The regulator states that Roche's drug is only to be used when the overall treatment cost, which includes staffing for administration and monitoring of the medicine and the treatment of side effects, does not exceed the cost of treatment with Taxotere.

26th November 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics